News

Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.

The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.

The video-driven platform equips ophthalmic practices with tools to standardize education, improve workflow, and foster technician engagement.

Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).

Maximizing treatment based on GA location, lesion progression, and morphologic retinal changes.

The agenda includes subspecialty days, evening events and partner programmes from practice management organisations

A young surgeon reflects on training, technology, and the human side of adopting new excimer laser platforms.

Join the American Academy of Ophthalmology's annual meeting for cutting-edge insights, networking, and engaging events from October 17-20 in Orlando.

Real-world insights emphasize identifying underlying causes to tailor treatment.

Research finding challenge the widely-held notion that cosmetic contact lenses are the safest technique for changing eye colour

Both have issued further statements regarding the deal.

The procedure showed positive effects on the electroretinography (ERG) (b-wave, oscillatory potentials), optomotor response, and contrast sensitivity in actively treated eyes compared with controls.

A stepwise guide to optimize astigmatism management in cataract surgery

A pair of studies, conducted in Taiwan and China, indicate that red light therapy could serve as an effective and safe alternative to atropine

From early experiences in India to fellowship training at Wills Eye Hospital, Dr. Ansari discusses how ophthalmologists can make a lasting impact worldwide.

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD

Learn how the YOURS Committee empowers young retina specialists through engaging educational initiatives, networking opportunities, and exam preparation resources.

Oculis plans to commence its PIONEER program, consisting of 3 trials, by the end of the year.

Catch up on this week's highlights in retina.

Discover key insights from leading ophthalmology experts at the AAO meeting, featuring presentations, posters, and innovative discussions from October 17-20.

NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).

Additionally, the company also received Clinical Trial Authorisation (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).